Matthew Henn

Microbial ecologist and entrepreneur with interest in translating scientific discoveries into transformative technologies and therapeutics. Tweets own opinions.

[Matthew Henn @microbiologic]

Thank you to the incredible team at Seres, the patients who have trusted us, and the many collaborators who have helped us to achieve this mission. #SeresProud #microbiome

[Matthew Henn @microbiologic]

Myself and a few others colleagues at Seres Therapeutics and Flagship Pioneering set out 11+ years ago to transform patients' lives with revolutionary microbiome therapeutics. Humbled today to have Seres named in the TIME100 Most Influential Companies. https://t.co/1gOCREBnGr

[Matthew Henn @microbiologic]

An exciting next step at Seres Therapeutics as we extend our technology to the global threat of antimicrobial resistant infections. #SeresProud #AMR #microbiome https://t.co/FFpXpWwYah

[Matthew Henn @microbiologic]

I am truly humbled to have had the opportunity to work with my colleagues at @SeresTX and @FlagshipPioneer, to work in an environment that is scientifically rigorous and data-driven, and where I’ve had the opportunity to better the lives of others.  #SeresProud #GSD #microbiome

[Matthew Henn @microbiologic]

Today @SeresTx marked an important milestone in the development of drugs that leverage millions of years of coevolution between microbes and humans for the prevention or treatment of diseases.  https://t.co/nZix8QPOZV

[Matthew Henn @microbiologic]

we charted an uncharted clinical and regulatory landscape; we never gave up on our commitment to patients.

[Seres Therapeutics @SeresTX]

BREAKING: The first orally administered #microbiota-based therapeutic has been approved by the U.S. FDA. Learn more: https://t.co/L78EZlc3tQ

[STAT @statnews]

The FDA approved a new drug from Seres Therapeutics that uses bacteria to treat a bowel disorder, making it the second microbiome therapy to hit the market. https://t.co/2d0qRyxKgv

[Matthew Henn @microbiologic]

Research into the #microbiome has the potential to fundamentally change public health, and I’m #SeresProud to be part of a company at the heart of it. https://t.co/X6JeH9xZIb https://t.co/Jvv7yRXHay

[Matthew Henn @microbiologic]

One year in, and it continues to be an honor to serve on the Board of Advisors for Life Science Cares Boston. That was one highlight for me this year, and there are many more that make me #SeresProud. Learn more. https://t.co/e4ENb7CSoR

[Matthew Henn @microbiologic]

November is #CdiffAwarenessMonth, a time to recognize #Cdiff patients and raise awareness of this serious and debilitating disease. #NovemberCdiffAwareness https://t.co/qzo2NPysax https://t.co/mm3X8DtyMX

[Matthew Henn @microbiologic]

Some reflections on the potential of microbiome therapeutics to help address the challenges we face with antimicrobial resistant infections. #antimicrobialresistance #amr #microbiome

https://t.co/N4gpEGOae4

[Matthew Henn @microbiologic]

@Jeffinerca Congratulations JP!

[Matthew Henn @microbiologic]

This is an exciting milestone for Seres and, if approved, takes us one step closer to delivering a new class of therapeutics with the potential to treat many serious diseases. I’m #SeresProud to be a part of this team. #microbiome #Cdiff https://t.co/Rf6OynN5Xc

[Matthew Henn @microbiologic]

Antibiotics are one of the greatest medical advances of modern medicine, but there can be downsides such as the loss of diversity of beneficial microbes in the GI that may lead to reduced protection from gut pathogens and possibly sepsis. https://t.co/DnNKDVtwlM